CORT (STOCKS)
Corcept Therapeutics Inc.
$42.250000
+0.340000 (+0.81%)
Prev close: $41.910000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joseph K. Belanoff
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,603.87M
- Employees
- 500
- P/E (TTM)
- 51.22
- P/B (TTM)
- 6.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.20 | $0.31 | -0.1060 | -34.64% |
|
Sep 2025 (Q3)
|
$0.16 | $0.14 | +0.0223 | +16.19% |
|
Jun 2025 (Q2)
|
$0.29 | $0.19 | +0.0987 | +51.59% |
|
Mar 2025 (Q1)
|
$0.17 | $0.15 | +0.0247 | +17.00% |
Financial Statements
| Revenues | $741.17M |
| Benefits Costs and Expenses | $652.66M |
| Cost Of Revenue | $13.39M |
| Costs And Expenses | $675.60M |
| Gross Profit | $727.78M |
| Nonoperating Income/Loss | $22.94M |
| Operating Expenses | $662.21M |
| Selling, General, and Administrative Expenses | $401.86M |
| Research and Development | $260.35M |
| Operating Income/Loss | $65.57M |
| Income/Loss From Continuing Operations After Tax | $106.11M |
| Income/Loss From Continuing Operations Before Tax | $88.51M |
| Income Tax Expense/Benefit | -$17.60M |
| Income Tax Expense/Benefit, Deferred | -$26.21M |
| Net Income/Loss | $106.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $106.11M |
| Net Income/Loss Available To Common Stockholders, Basic | $104.66M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.45M |
| Preferred Stock Dividends And Other Adjustments | $1.45M |
| Basic Earnings Per Share | $1.00 |
| Diluted Earnings Per Share | $0.87 |
| Basic Average Shares | 104,057,000 |
| Diluted Average Shares | 121,890,000 |
| Assets | $823.61M |
| Current Assets | $541.13M |
| Inventory | $12.35M |
| Prepaid Expenses | $22.98M |
| Other Current Assets | $505.80M |
| Noncurrent Assets | $282.48M |
| Fixed Assets | $2.09M |
| Other Non-current Assets | $280.38M |
| Liabilities | $191.71M |
| Current Liabilities | $172.27M |
| Accounts Payable | $34.45M |
| Other Current Liabilities | $137.82M |
| Noncurrent Liabilities | $19.44M |
| Equity | $631.90M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $631.90M |
| Liabilities And Equity | $823.61M |
| Net Cash Flow From Operating Activities | $163.38M |
| Net Cash Flow From Operating Activities, Continuing | $163.38M |
| Net Cash Flow From Investing Activities | $17.24M |
| Net Cash Flow From Investing Activities, Continuing | $17.24M |
| Net Cash Flow From Financing Activities | -$193.71M |
| Net Cash Flow From Financing Activities, Continuing | -$193.71M |
| Net Cash Flow | -$12.15M |
| Net Cash Flow, Continuing | -$13.10M |
| Comprehensive Income/Loss | $106.88M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $106.88M |
| Other Comprehensive Income/Loss | $770.00K |